Bial

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

BIAL Award in Biomedicine worth 300,000 Euros

Retrieved on: 
Wednesday, April 26, 2023
BioNTech, The New England Journal of Medicine, European Medical Association, The BMJ, European Research Council, Medical journal, COVID-19 vaccine, Perelman School of Medicine at the University of Pennsylvania, Medicina, Jury, University, Nature (journal), Medical Faculty Associates, Messenger, Bangladesh Technical Education Board, Harvard Medical School, Panel, Biology, COVID-19, Council, Saint Andrew's Society, Bial, Medical device, Nursing, Pharmaceutical industry, California Institute of Technology, Biomedicine, Psychology, Neuroscience

TROFA, Portugal, April 26, 2023 /PRNewswire/ -- The third edition of the BIAL Foundation's international award, the BIAL Award in Biomedicine, is now underway, with nominations open until 30 June. With the amount of 300 thousand Euros, this award aims to recognise a work of a broad biomedical nature with exceptional quality and scientific relevance results published within the last ten years.

Key Points: 
  • TROFA, Portugal, April 26, 2023 /PRNewswire/ -- The third edition of the BIAL Foundation's international award, the BIAL Award in Biomedicine, is now underway, with nominations open until 30 June.
  • With the amount of 300 thousand Euros, this award aims to recognise a work of a broad biomedical nature with exceptional quality and scientific relevance results published within the last ten years.
  • Candidates for this international award may be nominated by members of the Jury, members of the Scientific Board of the BIAL Foundation, previous BIAL Award winners, Scientific Societies, Boards or Deans of Medical Faculties, Heads of leading research institutes, and Boards or Heads of prestigious Academies.
  • The BIAL Award in Biomedicine takes place biannually, in odd-numbered years, alternating with the Prémio BIAL de Medicina Clínica.

Bangalore International Airport Limited Partners with IBM for Digital and IT Transformation

Retrieved on: 
Wednesday, July 21, 2021
Information technology, Computing, Companies, Kempegowda International Airport, IBM, Airport, Bial

ARMONK, N.Y. and BENGALURU, India, July 21, 2021 /PRNewswire/ -- IBM (NYSE: IBM) and Bangalore International Airport Limited (BIAL) -- operator of Kempegowda International Airport Bengaluru (KIAB/BLR Airport) -- today announced a ten-year agreement under which IBM and Kyndryl will provide best of breed IT solutions to create a new "Airport in a Box" platform that will support transforming the end-to-end travel experience for passengers at BLR Airport.

Key Points: 
  • ARMONK, N.Y. and BENGALURU, India, July 21, 2021 /PRNewswire/ -- IBM (NYSE: IBM ) and Bangalore International Airport Limited (BIAL) -- operator of Kempegowda International Airport Bengaluru (KIAB/BLR Airport) --today announced a ten-yearagreement under which IBM and Kyndryl will provide best of breed IT solutions to create a new "Airport in a Box" platform that will support transforming the end-to-end travel experience for passengers at BLR Airport.
  • Onethat is highly efficient, secure, and will enable a seamless travel experience for its passengers.
  • IBM and BIAL will work to ensure that the platform supports BIAL's commitment to sustainability and the community at large.
  • "We are excited to partner with IBM as part of our vision to make BLR Airport the Smart Airport-- a digitalized, seamlessly connected, intuitive airport," said Mr. Hari Marar, MD & CEO, BIAL.

BIAL Award in Biomedicine worth 300,000 Euros, nominations until 30 June

Retrieved on: 
Monday, June 7, 2021
Bial, University of Chile

PORTO, Portugal, June 7, 2021 /PRNewswire/ -- The second edition of the BIAL Award in Biomedicine is currently underway.

Key Points: 
  • PORTO, Portugal, June 7, 2021 /PRNewswire/ -- The second edition of the BIAL Award in Biomedicine is currently underway.
  • The Jury looks forward to receiving nominations from different groups of scientists, such as universities, societies, academies and research institutes.
  • Candidates for this award will be nominated by members of the jury, of the Foundation's Scientific Board, previous BIAL Award recipients, and Scientific Societies.
  • Among its many activities, highlights include the attribution of prizes, namely the Prmio BIAL de Medicina Clnica and the BIAL Award in Biomedicine.

BIAL Award in Biomedicine worth 300,000 Euros, nominations until 30 June

Retrieved on: 
Monday, June 7, 2021
Bial, University of Chile

PORTO, Portugal, June 7, 2021 /PRNewswire/ -- The second edition of the BIAL Award in Biomedicine is currently underway.

Key Points: 
  • PORTO, Portugal, June 7, 2021 /PRNewswire/ -- The second edition of the BIAL Award in Biomedicine is currently underway.
  • The Jury looks forward to receiving nominations from different groups of scientists, such as universities, societies, academies and research institutes.
  • Candidates for this award will be nominated by members of the jury, of the Foundation's Scientific Board, previous BIAL Award recipients, and Scientific Societies.
  • Among its many activities, highlights include the attribution of prizes, namely the Prmio BIAL de Medicina Clnica and the BIAL Award in Biomedicine.

BIAL Takes the Lead in Europe for the Commercialisation of Epilepsy Treatment, Zebinix® (eslicarbazepine acetate), Expanding Neurology Footprint

Retrieved on: 
Thursday, February 18, 2021
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Bial, Epilepsy, Anticonvulsants, Ureas, Health, Eslicarbazepine acetate, Epilepsy in animals, Chemistry, Zebinix® (eslicarbazepine acetate), Epilepsy, BIAL

BIAL takes the lead for the marketing and distribution of Zebinix (eslicarbazepine acetate) in Europe.

Key Points: 
  • BIAL takes the lead for the marketing and distribution of Zebinix (eslicarbazepine acetate) in Europe.
  • Following the end of this partnership, BIAL will take the lead for the ongoing marketing, promotion and distribution in Europe.
  • BIAL has over 10 years of experience of delivering life-improving medicines for neurological conditions such as epilepsy and Parkinsons disease.
  • For more information on BIAL: www.bial.com
    1- Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.

BIAL Goes Global With New US Research Center and Acquisition of Promising Parkinson's Disease Programs

Retrieved on: 
Thursday, October 1, 2020
Health, Genetics, Managed care, Research, Science, Pharmaceutical, Biotechnology, Bial, Parkinson, BIAL Biotech, BIAL

This new research center focused on genetically-defined Parkinsons disease is based in Cambridge, Massachusetts, a prominent biotech hub in the world.

Key Points: 
  • This new research center focused on genetically-defined Parkinsons disease is based in Cambridge, Massachusetts, a prominent biotech hub in the world.
  • View the full release here: https://www.businesswire.com/news/home/20201001005323/en/
    Simultaneously, BIAL announced that it has acquired worldwide rights of LTI-291 and all the Parkinsons disease research programs of Lysosomal Therapeutics Inc. (LTI) and taken on the entire R&D team.
  • The development of this new research center in the US, is a landmark of enormous relevance for us.
  • Were progressing from symptomatic treatment to an intervention in the mechanisms of the disease, which is very exciting for BIAL.

FDA approves ONGENTYS® ▼ (opicapone)

Retrieved on: 
Wednesday, April 29, 2020
FDA, Pharmaceutical, Health, Mental health, Health, Drugs, Catecholamines, Neurocrine Biosciences, Catechols, Opicapone, Bial, Carbidopa, L-DOPA, Parkinson's disease, Food and Drug Administration, Clinical trial, Opicapone 6, BIAL

BIAL announced today that the U.S Food and Drug Administration (FDA) has approved ONGENTYS (opicapone) as an add-on treatment to levodopa/carbidopa in patients with Parkinsons disease experiencing off episodes.

Key Points: 
  • BIAL announced today that the U.S Food and Drug Administration (FDA) has approved ONGENTYS (opicapone) as an add-on treatment to levodopa/carbidopa in patients with Parkinsons disease experiencing off episodes.
  • This approval is a landmark in BIALs ongoing commitment to the quality of life of Parkinsons patients and their caregivers.
  • We look forward to working with our partner in the U.S., Neurocrine Biosciences, to make this therapy available to patients.
  • The FDA approval of opicapone is supported by data from 38 clinical studies, including two multinational Phase III clinical studies (BIPARK-1 and BIPARK-2).

Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease

Retrieved on: 
Wednesday, July 10, 2019
Phenols, Aromatic compounds, Chemical compounds, Catechols, Nitrophenols, Neurocrine Biosciences, Opicapone, Catecholamines, Catechol-O-methyltransferase, Bial, Parkinson's disease, Neurocrine

With opicapone, we aim to prolong the benefits of levodopa by providing a new treatment option to patients with Parkinson's disease in the U.S.," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences.

Key Points: 
  • With opicapone, we aim to prolong the benefits of levodopa by providing a new treatment option to patients with Parkinson's disease in the U.S.," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences.
  • We look forward to working with the FDA to bring this new treatment option to patients coping with this debilitating disorder."
  • Neurocrine Biosciences in-licensed opicapone from BIAL in 2017 and has exclusive development and commercialization rights in the U.S. and Canada.
  • Opicapone, an investigational treatment for Parkinson's disease in the U.S., is a novel, once-daily, selective catechol-O-methyltransferase (COMT) inhibitor.